Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 2Solid Tumors 1Ovarian Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Endometrial Neoplasms 1Colorectal Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Carboplatin 79Paclitaxel 64pembrolizumab 63Cyclophosphamide 47Capecitabine 34Doxorubicin 31Taxes 28130-nm albumin-bound paclitaxel 28Albumin-Bound Paclitaxel 27Gemcitabine 20atezolizumab 18Epirubicin 18Cisplatin 18Bevacizumab 18olaparib 17sacituzumab govitecan 15Docetaxel 15eribulin 14toripalimab 13durvalumab 13camrelizumab 13Drug Therapy 12apatinib 9Trastuzumab 9Radiotherapy 9Specimen Handling 8Magnetic Resonance Spectroscopy 8Biopsy 8tislelizumab 7talazoparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Triple Negative Breast Neoplasms × inavolisib × Clear all
NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
26 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Hoosier Cancer Research Network

Phase 2 Terminated
52 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡